Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2
54
about 8.3 years
0.5–65
1 site in WA
What this study is about
This trial is testing how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy before a donor cord blood transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Sometimes the transplanted cells can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Total-Body Irradiation
- 2.Survey Administration
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), ciclosporin, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), Immunological Agents (Enzyme Inhibitors), thiotepa
infusion, injection, intravenous, injection (Injection)
Primary: Overall survival
Secondary: Incidence of adverse events
diagnostic, imaging, radiation
Oncology